Genocea Banking On Success With Herpes Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised $61 million in its February IPO, Genocea hopes 2015 will be another transformative year for the company, as it expects Phase II data for its herpes simplex virus vaccine, a potential first-in-class product.
You may also be interested in...
Genocea Gets An Injection Of Capital As Early-Stage Studies Progress
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
Genocea Biosciences Inc.
Genocea Biosciences Inc. is one of a growing number of companies betting that it can stimulate the body’s T-cell response against particular antigens, and so create vaccines against pathogens never before bested by man, such as malaria, herpes and chlamydia. Like others working to develop new vaccines, Genocea suspects that the ability to conjure cellular immunity on demand could offer not only prophylaxis, but also therapeutic options to individuals already infected by pathogens. Many believe that T-cell-stimulating vaccines could eventually help people whose own cells have become cancerous.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.